Correlation Between X4 Pharmaceuticals and Achilles Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both X4 Pharmaceuticals and Achilles Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining X4 Pharmaceuticals and Achilles Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between X4 Pharmaceuticals and Achilles Therapeutics PLC, you can compare the effects of market volatilities on X4 Pharmaceuticals and Achilles Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in X4 Pharmaceuticals with a short position of Achilles Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of X4 Pharmaceuticals and Achilles Therapeutics.

Diversification Opportunities for X4 Pharmaceuticals and Achilles Therapeutics

-0.65
  Correlation Coefficient

Excellent diversification

The 3 months correlation between XFOR and Achilles is -0.65. Overlapping area represents the amount of risk that can be diversified away by holding X4 Pharmaceuticals and Achilles Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Achilles Therapeutics PLC and X4 Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on X4 Pharmaceuticals are associated (or correlated) with Achilles Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Achilles Therapeutics PLC has no effect on the direction of X4 Pharmaceuticals i.e., X4 Pharmaceuticals and Achilles Therapeutics go up and down completely randomly.

Pair Corralation between X4 Pharmaceuticals and Achilles Therapeutics

Given the investment horizon of 90 days X4 Pharmaceuticals is expected to under-perform the Achilles Therapeutics. In addition to that, X4 Pharmaceuticals is 8.52 times more volatile than Achilles Therapeutics PLC. It trades about -0.02 of its total potential returns per unit of risk. Achilles Therapeutics PLC is currently generating about 0.1 per unit of volatility. If you would invest  102.00  in Achilles Therapeutics PLC on September 3, 2024 and sell it today you would earn a total of  6.00  from holding Achilles Therapeutics PLC or generate 5.88% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

X4 Pharmaceuticals  vs.  Achilles Therapeutics PLC

 Performance 
       Timeline  
X4 Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days X4 Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Achilles Therapeutics PLC 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Achilles Therapeutics PLC are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical indicators, Achilles Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.

X4 Pharmaceuticals and Achilles Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with X4 Pharmaceuticals and Achilles Therapeutics

The main advantage of trading using opposite X4 Pharmaceuticals and Achilles Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if X4 Pharmaceuticals position performs unexpectedly, Achilles Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Achilles Therapeutics will offset losses from the drop in Achilles Therapeutics' long position.
The idea behind X4 Pharmaceuticals and Achilles Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Complementary Tools

Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories